Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma

Sponsor
Shanghai Zhongshan Hospital
Study ID
NCT03510416
Phase
PHASE2
Status
Unknown

Conditions

  • Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    apatinib is a kind of Inhibitor of VEGFR-2
  • TACE — RADIATION
    Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE.

Study Details

Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization .

Key Dates

Start date
May 1, 2018
Status verified
Apr 2018
Primary completion
Jun 30, 2019
Completion
Dec 31, 2019

Study Design

Enrollment
22 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: apatinib combined with TACE
    Apatinib is administered after TACE 4-7 days, and TACE treatment is performed after discontinuation of apatinib for 4 days.Every 28 days is a cycle.

Primary Outcome Measure

Time To Progression [ Time Frame: From the date of first procedure of apatinib combined with TACE until the time when the disease progresses, assessed up to 14 months ]

Central Contacts